2:01 PM
 | 
Oct 23, 2017
 |  BC Extra  |  Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a led to functional disease control in eight of 10 patients. Replicor CSO Andrew Vaillant told BioCentury the company plans to start a U.S. Phase II trial of the combination next year.

The open-label trial...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >